13F Holdings
中文EN

BIIB BIOGEN INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 875045 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY2.3%
TTM net income YoY-78.4%
TTM EPS YoY-78.9%
Revenue 3-yr CAGR1.0%
Net income 3-yr CAGR-38.1%

Margins

Gross margin74.0%
Operating margin—
Net margin3.4%
FCF margin20.1%
EBITDA margin—

Returns

ROE1.9%
ROA1.1%
ROIC (approx.)—
Asset turnover0.34x

Leverage & solvency

Liabilities / assets41.0%
Debt / equity0.39x
Current ratio1.95x
Interest coverage—

Cash quality & payout

Operating cash flow / net income6.47x
Accruals ratio-6.2%
Payout ratio—
Capex / revenue1.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$9.89B$9.68B$9.84B$10.17B$10.98B
Cost of revenue$2.40B$2.31B$2.53B$2.28B$2.11B
Gross profit$7.49B$7.37B$7.30B$7.90B$8.87B
R&D expense$1.78B$1.98B$2.45B$2.23B$2.50B
SG&A expense$2.43B$2.40B$2.55B$2.40B$2.67B
Operating income————$2.84B
Interest expense$267.50M$250.30M$246.90M$246.60M$253.60M
Pretax income$1.56B$1.91B$1.30B$3.59B$1.75B
Income tax$263.60M$273.80M$135.30M$632.80M$52.50M
Net income$1.29B$1.63B$1.16B$3.05B$1.56B
EBITDA————$3.33B
EPS (basic)8.8311.218.0220.9610.44
EPS (diluted)8.7911.187.9720.8710.40
Weighted avg. shares (diluted)147.10M145.90M145.60M146.00M149.60M
Balance sheet
Cash & equivalents$3.01B$2.38B$1.05B$3.42B$2.26B
Short-term investments$807.20M$0$0$1.47B$1.54B
Receivables$1.34B$1.40B$1.66B$1.71B$1.55B
Inventory$2.17B$2.46B$2.53B$1.34B$1.35B
Current assets$8.97B$7.46B$6.86B$9.79B$7.86B
PP&E, net$3.06B$3.18B$3.31B$3.30B$3.42B
Goodwill$6.49B$6.48B$6.22B$5.75B$5.76B
Intangibles$9.18B$9.69B$8.36B$1.85B$2.22B
Total assets$29.44B$28.05B$26.84B$24.55B$23.88B
Current liabilities$3.35B$5.53B$3.43B$3.27B$4.30B
Short-term debt$0$1.75B$150.00M$0$999.10M
Long-term debt$6.29B$4.55B$6.79B$6.28B$6.27B
Total debt$6.29B$6.30B$6.94B$6.28B$7.27B
Total liabilities$11.18B$11.33B$12.05B$11.17B$12.92B
Shareholders' equity$18.26B$16.72B$14.80B$13.40B$10.90B
Net debt$3.28B$3.92B$5.89B$2.86B$5.01B
Shares outstanding146.80M145.80M144.90M144.00M147.00M
Cash flow statement
Operating cash flow$2.20B$2.88B$1.55B$1.38B$3.64B
Capital expenditure$153.80M$153.70M$277.00M$240.30M$258.10M
Free cash flow$2.05B$2.72B$1.27B$1.14B$3.38B
Investing cash flow-$1.37B-$799.20M-$4.10B$1.58B-$563.70M
Financing cash flow-$301.90M-$683.50M$149.30M-$1.75B-$2.09B
Depreciation & amortization$779.90M$673.20M$494.80M$518.40M$487.70M
Stock-based compensation$290.80M$291.20M$264.20M$254.10M$238.60M
Share buybacks—$0$0$750.00M$1.80B

Free plan shows the latest 5 periods; Pro shows all 19 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.